Financial Performance - The company reported a revenue of RMB 12,674,000 for the three months ended March 31, 2020, a decrease of 26.5% compared to RMB 17,275,000 for the same period in 2019[5]. - Gross profit for the same period was RMB 6,389,000, down from RMB 9,395,000 in the previous year, reflecting a gross margin decline[5]. - The company incurred a loss attributable to owners of RMB 2,109,000 for the quarter, compared to a profit of RMB 1,645,000 in the prior year[5]. - Operating loss for the quarter was RMB 1,326,000, a significant decline from an operating profit of RMB 2,109,000 in the same quarter of 2019[5]. - The total comprehensive income for the period was a loss of RMB 154,000, compared to a total comprehensive income of RMB 3,314,000 in the previous year[5]. - Basic and diluted loss per share was RMB 0.28, compared to earnings of RMB 0.22 per share in the same period last year[5]. - The company reported financing costs of RMB 738,000 for the quarter, which is an increase from RMB 70,000 in the previous year[5]. - The company’s administrative expenses were RMB 6,156,000, up from RMB 5,056,000 in the prior year, indicating increased operational costs[5]. - Other income for the quarter was RMB 416,000, a decrease from RMB 467,000 in the same period of 2019[5]. Revenue Breakdown - Revenue from funeral services and cremation services was RMB 12,078,000, down 26.5% from RMB 16,346,000 in the previous year[18]. - Revenue from the Chinese market accounted for 95.3% of total revenue, slightly down from 95.5% in the previous year[29]. - Revenue from Taiwan was RMB 212,000, representing 1.7% of total revenue, down from 3.0% in the previous year[29]. - Revenue from the Chinese market was approximately RMB 12,078,000, a decrease of about 26.8% compared to the previous period's RMB 16,490,000[30]. - The segment providing funeral, cremation, and cemetery services in China contributed approximately RMB 12,078,000, down from RMB 16,344,000, while sales of stem cells and immune cells recorded zero revenue, down from RMB 146,000[30]. - Revenue from Taiwan was approximately RMB 212,000, a decrease of about 59.6% from RMB 525,000 in the previous period, while revenue from Hong Kong increased by approximately 101.6% to RMB 258,000 from RMB 128,000[33][35]. - The group's total revenue for the period was approximately RMB 12,674,000, a decrease of about 26.6% from RMB 17,275,000 in the previous period, primarily due to government-imposed lockdowns[37]. - Sales costs for the period were approximately RMB 6,285,000, a decrease of about 20.2% from RMB 7,880,000, attributed to reduced revenue across all business segments[37]. Strategic Initiatives - The board believes that the funeral service business remains stable due to its concentration in densely populated cities in China, while the global biotechnology industry is experiencing rapid growth driven by increasing demand for healthcare services[42]. - The group has initiated a diversification strategy to actively engage in the cell industry, including investments in cell culture media research and development[42]. - The group plans to continue developing its funeral business while exploring opportunities in the cell industry through investments, mergers, and acquisitions to optimize its business structure and create new profit growth points[44]. - The group maintains a prudent financial management strategy and aims to leverage its market advantages to enhance cooperation with foreign biotechnology companies[42]. Corporate Governance - As of March 31, 2020, Hong Kong Gaoqi holds 220,475,000 shares, representing 29.69% of the company's issued share capital[47]. - The company did not have any significant contracts that directors had a direct or indirect interest in during the reporting period[51]. - The company faced delays in publishing its audited financial results for the year ended December 31, 2019, due to travel restrictions related to COVID-19[59]. - The audit committee, consisting of three independent non-executive directors, reviewed the unaudited consolidated financial statements and confirmed compliance with applicable accounting standards[57]. - The company did not engage in any purchase, sale, or redemption of its listed securities during the reporting period[56]. - No directors or major shareholders had interests in any competing businesses during the reporting period[55]. - The company did not disclose any rights for directors to purchase shares or debt securities during the reporting period[52]. - There were no known individuals with 5% or more voting rights at the company's shareholder meetings as of March 31, 2020[50]. - The company did not establish any management contracts for significant parts of its business during the reporting period[53]. - The company has not disclosed any new products, technologies, or market expansion strategies in the provided documents[46].

活出精彩 Live life to the Fullest Third Quarterly Report 2019 活出精彩 Live life to the Fullest 第三季度報告2019 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為中小型公司提供一個上市的市場，此等公司相比起其他 在主板上市的公司帶有較高投資風險。有意投資的人士應了解投資於該等 公司的潛在風險，並應經過審慎周詳的考慮後方作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於主板 買賣之證券承受較大的市場波動風險，同時無法保證在GEM買賣的證券會 有高流通量的市場。 香港交易及結算所有限公司及聯交所對本報告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本報告全部或任何部 分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 本報告的資料乃遵照聯交所GEM證券上市規則（「GEM上市規則」）而刊載， 旨在提供有關中國生命集團有限公司（「本公司」）的資料。本公司的董事（「董 事」）願就本報告的資料共同及個別地承擔全部責任。 各董事在作出一切合理查詢後，確認就其 ...

Financial Performance - For the six months ended June 30, 2019, the company reported total revenue of RMB 31,705,000, an increase of 0.62% compared to RMB 31,509,000 for the same period in 2018[7]. - The gross profit for the same period was RMB 16,047,000, representing a gross margin of 50.6%, compared to RMB 15,309,000 and a gross margin of 48.7% in 2018[7]. - The company incurred a loss of RMB 1,969,000 for the six months ended June 30, 2019, an improvement from a loss of RMB 2,577,000 in the prior year[9]. - Basic and diluted loss per share for the six months was RMB 0.03, compared to a loss of RMB 0.39 per share in the same period of 2018[9]. - The total comprehensive income for the period, after tax, was RMB 622,000, compared to RMB 3,406,000 in the previous year[9]. - The company reported a net profit before tax of RMB 201 thousand for the six months ended June 30, 2019, a significant recovery from a loss of RMB 2,504 thousand in the same period of 2018[62]. - The group recorded a profit attributable to owners of approximately RMB 242,000, compared to a loss of RMB 2,869,000 in the previous period, resulting in earnings per share of RMB 0.03 compared to a loss of RMB 0.39 per share previously[143]. Cash Flow and Liquidity - Cash and cash equivalents as of June 30, 2019, amounted to RMB 115,764,000, a decrease from RMB 205,272,000 at the end of 2018[12]. - The company reported a net cash outflow from operating activities of RMB (2,565) thousand for the six months ended June 30, 2019, compared to RMB (2,364) thousand for the same period in 2018[22]. - The net cash inflow from investing activities was RMB 14,146 thousand for the six months ended June 30, 2019, compared to a net outflow of RMB (437) thousand in 2018[22]. - The company experienced a net cash outflow from financing activities of RMB (355) thousand in the first half of 2019, an improvement from RMB (967) thousand in the same period of 2018[22]. - The total cash and cash equivalents increased by RMB 11,226 thousand to RMB 115,764 thousand as of June 30, 2019, compared to RMB 101,345 thousand at the end of June 2018[22]. - The group maintained a healthy financial position with cash and bank balances of approximately RMB 115,764,000 as of June 30, 2019, up from RMB 103,467,000 at the end of 2018[145]. Assets and Liabilities - The company's total assets less current liabilities stood at RMB 149,700,000, an increase from RMB 111,043,000 in the previous year[12]. - The company’s total liabilities as of June 30, 2019, were RMB (161,984) thousand, reflecting a significant increase from RMB (153,297) thousand in the previous year[18]. - The total assets of the company as of June 30, 2019, were RMB 255,074 thousand, up from RMB 227,661 thousand as of December 31, 2018, showing an increase of approximately 12.06%[59]. - The total liabilities increased to RMB 160,228 thousand as of June 30, 2019, from RMB 123,818 thousand at the end of 2018, marking a rise of about 29.43%[59]. - The company’s lease liabilities include both current and non-current portions, with current lease liabilities amounting to RMB 4,178,000 and non-current lease liabilities at RMB 38,249,000[47]. Business Strategy and Future Outlook - The company plans to focus on expanding its market presence and enhancing its product offerings in the upcoming periods[6]. - The company is focused on expanding its services in the funeral and related sectors, as well as in the sale of burial plots and tombstones, which are key areas for future growth[24]. - The company has introduced a new business segment focused on stem cell and immune cell services, which is expected to be a major value driver[54]. - The company plans to continue its focus on the funeral business while actively developing the cell industry through various investment collaborations[157]. - The company aims to create value for shareholders by seeking new business opportunities and optimizing its business structure for sustainable growth[157]. Accounting and Financial Reporting - The board of directors confirmed that the financial information presented is accurate and complete, with no misleading elements[2]. - The adoption of Hong Kong Financial Reporting Standard 16 resulted in an increase of RMB 31,513 thousand in right-of-use assets and a total lease liability of RMB 40,363 thousand as of June 30, 2019[36]. - The financial impact of HKFRS 16 did not have a significant effect on the earnings per share for the period[38]. - The total equity decreased by RMB 11,648 thousand due to the adjustments made under HKFRS 16[36]. - The audit committee, composed of three independent non-executive directors, reviewed the financial statements for the six months ended June 30, 2019, and confirmed compliance with applicable accounting standards[188]. Revenue Breakdown - The revenue from funeral services was RMB 29,958 thousand, an increase from RMB 29,234 thousand in the previous year, reflecting a growth of about 2.48%[74]. - The revenue from stem cell and immune cell sales was RMB 301 thousand for the six months ended June 30, 2019, compared to no revenue in the same period of 2018[67]. - Revenue from the sale of burial plots and tombstones was RMB 175 thousand for the six months ended June 30, 2019, up from RMB 123 thousand in the same period of 2018, indicating a growth of approximately 42.24%[67]. - The group's revenue from the Chinese funeral services business increased by approximately 2.5% compared to the same period last year, reaching RMB 29,958,000, which accounts for 94.5% of total revenue[134]. - Revenue from the Taiwan market decreased by approximately 8.3%, totaling RMB 1,308,000, representing 4.1% of total revenue[139]. - Revenue from the Hong Kong market saw a significant decline of 63.2%, amounting to RMB 264,000, which is 0.8% of total revenue[139]. Cost Management - Employee costs, including director remuneration, rose to RMB 9,583,000 for the six months ended June 30, 2019, up from RMB 7,991,000 in 2018, reflecting a 20% increase[79]. - Sales costs decreased by approximately 3.3% to about RMB 15,658,000 from RMB 16,200,000, attributed to cost control measures in funeral services[142]. - Administrative expenses were approximately RMB 9,484,000, down about 15.8% from RMB 11,261,000, reflecting effective cost control measures[142]. Shareholder Information - As of June 30, 2019, Hong Kong Gaoqi holds 220,475,000 shares, representing approximately 29.69% of the company's issued share capital[160]. - The weighted average number of ordinary shares for the six months ended June 30, 2019, remained unchanged at 742,500,000 shares[91]. - The stock option plan allows for a maximum of 74,250,000 shares to be issued, equivalent to 10% of the total issued shares as of the mid-term report date[171]. - The total number of shares that may be issued under the stock option plan and any other plans shall not exceed 30% of the total issued shares at any time[173].

活出精彩 Live life to the Fulle GROUP LIMITED SINO-LIFE 中國生命集團有 限 公 司 於開曼群島註冊成立的有限公司 股份代號:8296 2019 第一李度報告 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為中小型公司提供一個上市的市場，此等公司相比起其他 在聯交所上市的公司帶有較高投資風險。有意投資的人士應了解投資於該 等公司的潛在風險，並應經過審慎周詳的考慮後方作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於主板 買賣之證券承受較大的市場波動風險，同時無法保證在GEM買賣的證券會 有高流通量的市場。 香港交易及結算所有限公司及聯交所對本報告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本報告全部或任何部 分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 本報告的資料乃遵照聯交所的GEM證券上市規則（「GEM上市規則」）而刊 載，旨在提供有關中國生命集團有限公司（「本公司」）的資料。本公司的董 事（「董事」）願就本報告的資料共同及個別地承擔全部責任。 各董事在作出一切合理查詢 ...

活出精歌 Live life to Fulles SINO-LIFE GROUP LIMITED 中國 生 市 集 限 国 足 巨 信 Incorporated in the Cayman Islands with limited liability 於 関曼群島註冊成立的有限公司 Stock Code 股份代號 : 8296 2018 Annual Report 年報 CHARACTERISTICS OF GEM OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE "STOCK EXCHANGE") GEM has been positioned as a market designed to accommodate small and mid-sized companies to which a higher investment risk may be attached than other companies listed on the Stock Exchange. Prospective investors should be aware of the ...